INFORMATIONAL BROCHURE PENTAVALENT BOTULINUM TOXOID

File: 120396_sep96_decls46_0002.txt
Page: 0002
Total Pages: 8

Subject: INFORMATIONAL BROCHURE PENTAVALENT BOTULINUM TOXOID             

Unit: OTSG        

Parent Organization: HSC         

Box ID: BX003204

Folder Title: INFO PAPER PENTAVALENT ABCDE BOTULINUM TOXOID                                                   

Document Number:          1

Folder SEQ  #:         19


        99/07/90 15: 37  '&301 663 2982         HQ U-              OTSG              002/ 008



      SENT BY:CDC COM, CENTER      9- 6-90   8:01   ATLANTA GEORUIA USA-




                                        IntoMational Brochure
                                Pontavalont (JWCDZ) BotUlinum Tozoid




                    av    t (ABCDZ) Bolulinum toxoid AI&Minwn-Phosphatp Adsorbed is
               a combination of aluminum phoophate-adsorbod toxcid derived from
               formalin-iaaetivated, partially purified types a,z,r,, Di and R
               botulinum toxins.       Each vial contains 0.022% fomaldehyde and
               I:lOtOOO thitneronal an a preservative. The currently distributed--
               tozoid is n=ufactur*d by the Michigan Department of Public Ilealth.



               Administration and Damage

               BHA" WGLL' before withdrawing each dome.                Do not inject
               intracutarieously or into suportiotat structures. A 48 hour post
               vaccine arm examination in required following each inoculation.
               The first injection La represented by week 0. There is a 2 week
               interval between the first and second injection and it 12 week
               interval between the first and third injection.


                     Initial Vaticinat ign s@ elU - 0. 3 ml       subcutaaac@@@. CL-
                                                     2-12 weeks.

                     Fitgt Booster 0.3 ml            Bubcutansounly 12 months after
                                       the fi;stlinjection of the initial series.
                     subsimat Doo@terst .0.3 ml. @ subcutaneously at 2 year
                                              int*rvals, based on antitoxin titers.

                     Bubseament  boosters arm not tg be adminigtgred until after
               g*rum specimens   are checked for antit2xin levels by CDC.


               antitoxin levels against the toxin type 2 and/or 3 is evaluated at
  A report   in -sent to the clinical investigator indicating
               whether or not a booster is needed.          it the immunity@l*vel to
               ad* uate (sor= titers of 1:16 or 0.15 - 0.30 lu antitoxin per
               ml.1, the booster should not be considered for another two years at
               which tim* the im=ity level should be reassessed.

Document 8 f:/Week-36/BX003204/INFO PAPER PENTAVALENT ABCDE BOTULINUM TOXOID/informational brochure pentavalent botulinum tox:1122961634164
Control Fields 17
File Room = sep96_declassified
File Cabinet = Week-36
Box ID = BX003204
Unit = OTSG
Parent Organization = HSC
Folder Title = INFO PAPER PENTAVALENT ABCDE BOTULINUM TOXOID
Folder Seq # = 19
Subject = INFORMATIONAL BROCHURE PENTAVALENT BOTULINUM TOX
Document Seq # = 1
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 22-NOV-1996